Highlighted Text:
Show |
Hide
Full text loading...
Chapter 30 : Screening for Bioactivity
Author:
Hans-Peter Fiedler1
VIEW AFFILIATIONS
HIDE AFFILIATIONS
Affiliations:
1: Mikrobiologisches Institut, Universität Tübingen, Auf der Morgenstelle 28, D-72076 Tübingen, Germany
Content Type: Monograph
Publication Year:
2004
Category: Environmental Microbiology; Applied and Industrial Microbiology
Book DOI:
10.1128/9781555817770
Chapter DOI:
10.1128/9781555817770.ch30
MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Preview this chapter:
Screening for Bioactivity, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555817770/9781555812676_Chap30-1.gif /docserver/preview/fulltext/10.1128/9781555817770/9781555812676_Chap30-2.gif
Abstract:
The present situation in the screening for bioactive compounds is determined by the nearly unlimited capacity in the throughput of assays. The assays include classical antibacterial assays, classical antifungal assays, antitumor assays, enzyme inhibititory assays, antiparasitic assays, herbicidal assays, and algicidal assays. Alexander Fleming was one of the first scientists who used the agar plate diffusion assay to detect antibacterial activity. Most assays are focused on the inhibition of the polysaccharide network of the cell wall of many fungi, which consists of β-1,3-glucan, chitin, and mannan. One of the most promising new antifungals that were detected as glucan synthase inhibitors is the echinocandin lipopeptide group. Antitumor assays for high-throughput screening are mainly based on the specific inhibition of factors belonging to regulatory cascades. Such assays include the inhibition of protein-tyrosin phosphatases, which control the cell cycle or the inhibition of protein-tyrosin kinases. Chemical screening is focused on the chemical diversity produced by microorganisms and on the assumption that each secondary metabolite produced has or had a biological function in the producing organism. Zahner and coworkers modified the method with regard to staining reagents, sample preparation, and variation of culture conditions of the microorganisms, and his group described numerous secondary metabolites having antibacterial, antifungal, antitumor, enzyme inhibitory, or insecticidal activities.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
Key Concept Ranking
- Antibacterial Agents
- 0.60315293
- Cyclic Polypeptide Antibiotics
- 0.4560269
- High-Performance Liquid Chromatography
- 0.44325864
- Cell Wall Biosynthesis
- 0.4382782
0.60315293
Figures
Screening for Bioactivity
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555817770.chap30-1,webId=/content/author/10.1128/9781555817770.chap30-1,properties={foaf_givenname=Hans-Peter, foaf_name=Hans-Peter Fiedler, foaf_surname=Fiedler, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555817770.chap30-aff1]]}]]
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-1
Figure 1
Agar plate diffusion assay using Bacillus subtilis as the test organism and agar pieces from actinomycetes cultures. Reprinted from Zahner (1965) by permission of Springer-Verlag.
10.1128/9781555817770/fig30-1_thmb.gif
10.1128/9781555817770/fig30-1.gif
Figure 1
Agar plate diffusion assay using Bacillus subtilis as the test organism and agar pieces from actinomycetes cultures. Reprinted from Zahner (1965) by permission of Springer-Verlag.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-2
Figure 2
Agar plate diffusion assay using Streptomyces viridochromogenes as the test organism. Test solutions are applied on filter disks.
10.1128/9781555817770/fig30-2_thmb.gif
10.1128/9781555817770/fig30-2.gif
Figure 2
Agar plate diffusion assay using Streptomyces viridochromogenes as the test organism. Test solutions are applied on filter disks.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-3
Figure 3
Structure of rifampin, a semisynthetic therapeutic agent against tuberculosis.
10.1128/9781555817770/fig30-3_thmb.gif
10.1128/9781555817770/fig30-3.gif
Figure 3
Structure of rifampin, a semisynthetic therapeutic agent against tuberculosis.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-4
Figure 4
Thienamycin, a broad-spectrum antibacterial beta-lactam antibiotic produced by Streptomyces cattleya.
10.1128/9781555817770/fig30-4_thmb.gif
10.1128/9781555817770/fig30-4.gif
Figure 4
Thienamycin, a broad-spectrum antibacterial beta-lactam antibiotic produced by Streptomyces cattleya.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-5
Figure 5
Bulging or curling effect caused by inhibitors of the fungal cell wall biosynthesis on the hyphae of Botrytis cinerea; (a) normal hyphae, (b) abnormal hyphae.
10.1128/9781555817770/fig30-5_thmb.gif
10.1128/9781555817770/fig30-5.gif
Figure 5
Bulging or curling effect caused by inhibitors of the fungal cell wall biosynthesis on the hyphae of Botrytis cinerea; (a) normal hyphae, (b) abnormal hyphae.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-6
Figure 6
Structure of bleomycin, an antitumor antibiotic produced by Streptomyces verticillatus.
10.1128/9781555817770/fig30-6_thmb.gif
10.1128/9781555817770/fig30-6.gif
Figure 6
Structure of bleomycin, an antitumor antibiotic produced by Streptomyces verticillatus.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-7
Figure 7
HMG-CoA reductase inhibitors of the compactin type (statins), isolated from various fungi.
10.1128/9781555817770/fig30-7_thmb.gif
10.1128/9781555817770/fig30-7.gif
Figure 7
HMG-CoA reductase inhibitors of the compactin type (statins), isolated from various fungi.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-8
Figure 8
Structures of anthelminthic avermectins produced by Streptomyces avermitilis.
10.1128/9781555817770/fig30-8_thmb.gif
10.1128/9781555817770/fig30-8.gif
Figure 8
Structures of anthelminthic avermectins produced by Streptomyces avermitilis.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
/content/10.1128/9781555817770.chap30.fig30-9
Figure 9
Structure of simocyclinones (antibacterial and antitumor antibiotics), inhibitors of gyrase and protein kinase, produced by Streptomyces antibioticus Tü 6040.
10.1128/9781555817770/fig30-9_thmb.gif
10.1128/9781555817770/fig30-9.gif
Figure 9
Structure of simocyclinones (antibacterial and antitumor antibiotics), inhibitors of gyrase and protein kinase, produced by Streptomyces antibioticus Tü 6040.
Citation:
Fiedler H.
2004.
Screening for Bioactivity,
p 324-335.
In
Bull A (ed),
Microbial Diversity and Bioprospecting.
ASM Press, Washington, DC.
doi: 10.1128/9781555817770.ch30
References
/content/book/10.1128/9781555817770.chap30
1.
Alberts, A. W.,, J. Chen,, G. Kuron,, V. Hunt,, J. Huff,, C. Hoffman,, J. Rothrock,, M. Lopez,, H. Joshua,, E. Harris,, A. Patchett,, R. Monaghan,, S. Currie,, E. Stapley,, G. Albers-Schonberg,, O. Hensens,, J. Hirschfield,, K. Hoogsteen,, L. Liesch,, and J. Springer. 1980. Mevilonin: a potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA 77: 3957– 3961.
2.
Anke, H.,, and O. Sterner. 1997. Nematicidal metabolites from higher fungi. Curr. Org. Chem. 1: 361– 374.
3.
Arcamone, F.,, G. Cassinelli,, G. Fantini,, A. Grein,, P. Orezzi,, C. Pol,, and C. Spalla. 1969. Adriamycin, 14-hydroxydaunomycin, a new antitumor compound from S. peucetius var. caesius. Biotechnol. Bioeng. 11: 1101– 1110.
4.
Benz, F.,, F. Knüsel,, J. Nüesch,, H. Treichler,, and W. Voser. 1974. Echinocandin B. Ein neuartiges Polypeptid-Antibiotikum aus Aspergillus nidulans var. echinulatus: Isolierung und Bausteine. Helv. Chim. Acta 57: 2459– 2477.
5.
Bérdy, J. 1995. Are actinomycetes exhausted as a source of secondary metabolites? Biotekhnologiya 7: 3– 23.
6.
Blizzard, T. A.,, C. L. Ruby,, H. Mrozik,, F. A. Preiser,, and M. H. Fisher. 1989. Brine shrimp ( Artemia salina) as a convenient bioassay for avermectin analogs. J. Antibiot. 42: 1304– 1307.
7.
Brian, P. W.,, P. J. Curtis,, and H. Hemming. 1946. A substance causing abnormal development of fungal produced by Penicillium janczewskii. I. Biological assay, production and isolation of "curling factor." Trans. Br. Mycol Soc. 29: 173– 187.
8.
Brockmann, H.,, and W. Henkel. 1950. Pikromycin, ein neues Antibiotikum aus Actinomyceten. Naturwissensch. 37: 138– 139.
9.
Brockmann, H.,, and K. Bauer. 1950. Rhodomycin, ein rotes Antibiotikum aus Actinomyceten. Naturwissensch. 37: 492– 493.
10.
Brotzu, G. 1948. Richerche su di un nuovo antibiotico. Lavori Dell Institute d'Igiene di Cagliari 1948: m10– 11.
11.
Brown, A. G.,, T. C. Smale,, T. J. King,, R. Hasenkamp,, and R. H. Thompson. 1976. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J. Chem. Soc. Perkin Trans. 1: 1165– 1170.
12.
Bryskier, A. 2000. Cephems: fifty years of continuous research. J. Antibiot. 53: 1028– 1037.
13.
Burg, R. W.,, B. M. Miller,, E. E. Baker,, J. Bimbaum,, S. A. Currie,, R. Hartman,, Y. L. Kong,, R. L. Monaghan,, G. Olson,, I. Putter,, J. B. Tunac,, H. Wallick,, E. O. Stapley,, R. Oiwa,, and S. Omura. 1979. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob. Agents Chemother. 15: 361– 367.
14.
Cooper, K. E., 1963. The theory of antibiotic inhibition, p. 1– 86. In D. Kavanagh (ed.), Analytical Microbiology. Academic Press, New York, N.Y.
15.
Dähn, U.,, H. Hagenmaier,, H. Höhne,, W. A. König,, G. Wolf,, and H. Zähner. 1976. Nikkomycin, ein neuer Hemmstoff der Chitin-synthese bei Pilzen. Arch. Microbiol. 107: 143– 160.
16.
Debono, M.,, and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. An. Rev. Microbiol. 48: 471– 497.
17.
Debono, M.,, B. J. Abbott,, J. R. Turner,, L. C. Howard,, and R. S. Gordee. 1988. Synthesis and evaluation of LY121019, a member of a series of semi-synthetic analogues of the antifungal lipopeptide echinocandin B. Ann. N. Y. Acad. Sci. 544: 152– 167.
18.
Dreyfuss, M.,, E. Haerri,, H. Hofmann,, H. Kobel,, W. Pache,, and H. Tscherter. 1976. Cyclosporin A and C. New metabolites from Trichoderma polysporum (Link ex Pers.) Rifai. Eur.J. Appl. Microbiol. 3: 125– 133.
19.
Dubos, R. L. 1939. Bactericidal agent extracted from a soil bacillus. I. Preparation of the agent. Its activity in vitro. J. Exp. Med. 70: 1– 10.
20.
Dubost, M.,, P. Ganter,, R. Maral,, L. Ninet,, S. Pinnert,, J. Preud'Homme,, and G. H. Werner. 1963. Un nouvel antibiotique a propriétés cytostatiques: la rubidomycine. CR. Acad. Sci. Paris 257: 1813– 1815.
21.
Dürkheimer, W. 1975. Tetracyclines: chemistry, biochemistry, and structure-activity relations. Angew. Chem. 14: 721– 734.
22.
Ehrlich, J.,, Q. R. Bartz,, R. M. Smith,, D. A. Joslyn,, and P. R. Burkholder. 1947. Chloromycetin, a new antibiotic from a soil actinomycete. Science 106: 417.
23.
Endo, A. 1979. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. J. Antibiot. 32: 852– 854.
24.
Endo, A.,, M. Kuroda,, and Y. Tsujita. 1976. ML-236a, ML-236b, and ML-236c, new inhibitors of cholesterogenesis produced by Penicillium citrum. J. Antibiot. 29: 1346– 1348.
25.
Fiedler, H.-P.,, and H. Zähner,. 2001. Screening for new secondary metabolites from microorganisms, p. 16– 51. In V. Braun, and F. Götz (ed.), Microbial Fundamentals of Biotechnology. Wiley-VCH, Weinheim, Germany.
26.
Fiedler, H.-P.,, T. Schüz,, and H. Decker,. 1993. An overview of nikkomycins: history, biochemistry, and applications, p. 325– 352. In J. W. Rippon, and R. A. Fromtling (ed.), Cutaneous Antifungal Agents: Compounds in Clinical Practice and Development. Marcel Dekker, New York, N.Y.
27.
Fleming, A. 1922. Remarkable bacteriolytic element found in tissues and secretions. Proc. R. Soc. 93B: 306– 317.
28.
Fleming, A. 1929. The antibacterial action of cultures of a Penicillium with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10: 226– 236.
29.
Flynn, E. H. 1972. Cephalosporins and Penicillins. Chemistry and Biology. Academic Press, New York, N.Y.
30.
Galaktionov, K.,, X. Chen,, and D. Beach. 1996. CdC25 cell-cycle phosphatase as a target of c-myc. Nature 382: 511– 517.
31.
Gottlieb, D.,, F. K. Bhattacharyya,, H. W. Anderson,, and H. E. Carter. 1948. Some properties of an antibiotic obtained from a species of Streptomyces. J. Bacteriol. 55: 409– 417.
32.
Grein, A.,, C. Spalla,, A. Di Marco,, and G. Canevazzi. 1963. Descrizione e classificazione di un attinomicete ( Streptomyces peuticus sp. nova) productore di una sostanza ad attivita antitumorale: la daunomicina. G. Microbiol. 11: 109– 118.
33.
Grove, D. C.,, and W. A. Randell. 1950. Assay Methods of Antibiotics. Med. Encyclopaedia, New York, N.Y.
34.
Harned, R. L.,, P. H. Hidy,, and E. K. La Baw. 1955. Cycloserine. I. A preliminary report. Antibiot. Chemother. 5: 204– 205.
35.
Harris, D. A.,, M. Ruger,, M. A. Reagan,, F. J. Wolf,, R. L. Peck,, H. Wallick,, and H. B. Woodruff. 1955. Discovery, development and antimicrobial properties of D-4-amino-3-isoxazolidone (oxamycin), a new antibiotic produced by S. garyphalus n. sp. Antibiot. Chemother. 5: 183.
36.
Hazen, E. L.,, and R. Brown. 1950. Two antifungal agents produced by a soil actinomycete. Science 112: 423.
37.
Hendlin, D.,, E. O. Stapley,, M. Jackson,, H. Wallick,, A. K. Miller,, F. J. Wolf,, T. W. Miller,, L. Chaiet,, F. M. Kahan,, E. L. Foltz,, H. B. Woodruff,, J. M. Mata,, S. Hernandez,, and S. Mochales. 1969. Phosphonomycin, a new antibiotic produced by strains of streptomycetes. Science 166: 122– 123.
38.
Henkel, T.,, R. M. Brunne,, H. Muller,, and F. Reichel. 1999. Statistische Untersuchung zur Strukturkomplexität von Naturstoffen und synthetischen Substanzen. Angew. Chem. 111: 688– 691.
39.
Hill, D. C.,, S. K. Wrigley,, and L. J. Nisbet. 1998. Novel screen methodologies for identification of new microbial metabolites with pharmaceutical activity. Adv. Biochem. Eng. Biotechnol. 59: 73– 121.
40.
Hori, M.,, K. Kakiki,, and T. Misato. 1974. Further study on the relation of polyoxin structure to chitin synthetase inhibition. Agric. Biol. Chem. 38: 691– 698.
41.
Kahan, J. S.,, F. M. Kahan,, R. Goegelmann,, S. A. Currie,, M. Jackson,, E. O. Stapley,, T. W. Mille,, A. K. Miller,, D. Hendlin,, S. Mochales,, S. Hernandez,, H. B. Woodruff,, and J. Birnbaum. 1979. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot. 32: 1– 12.
42.
Komiyama, K.,, and S. Funayama,. 1992. Antitumor agents, p. 79– 103. In S. Omura (ed.), The Search for Bioactive Compounds from Microorganisms. Springer-Verlag, New York, N.Y.
43.
König, W. A.,, K.-P. Pfaff,, W. Loeffler,, D. Schanz,, and H. Zähner. 1978. Ethericin A: Isolierung, Charakterisierung und Strukturaufklärung eines neuen, antibiotisch wirksamen Diphenylethers. Liebigs. Ann. Chem. 1978: 1289– 1296.
44.
Kuhn, W.,, and H.-P. Fiedler. 1995. Sekundärmetabolismus bei Mikroorganismen. Attempto Verlag, Tübingen, Germany.
45.
Levitzki, A.,, and A. Gazit. 1995. Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782– 1788.
46.
Maeda, K.,, H. Kosaka,, K. Yagishita,, and H. Umezawa. 1956. A new antibiotic, phleomycin. J. Antibiot. 9: 82– 85.
47.
Maier, A.,, J. Müller,, P. Schneider,, H.-P. Fiedler,, I. Groth,, F. S. K. Tayman,, F. Teltschik,, C. Günther,, and G. Bringmann. 1999. (2E, 4Z)-Decadienoic acid and (2E, 4Z,7Z)-decatrienoic acid, two herbicidal metabolites from Streptomyces viridochromogenes Tü 6105. Pestic. Sci. 55: 733– 739.
48.
McGuire, J. M.,, R. L. Bunch,, R. C. Anderson,, H. E. Boaz,, E. H. Flyan,, H. M. Powell,, and J. W. Smith. 1952. “Ilotycin,” a new antibiotic. Antibiot. Chemother. 2: 281– 283.
49.
Michael, A. S.,, C. G. Thompson,, and M. Abramovitz. 1956. Artemia salina as a test organism for bioassay. Science 123: 464.
50.
Murao, S.,, and K. Ohyama. 1975. New amylase inhibitor (S-AI) from Streptomyces diastaticus var. amylostaticus No. 2476. Agric. Biol. Chem. 39: 2271– 2273.
51.
Newton, G. G. F.,, and E. P. Abraham. 1953. Cephalosporin C, a new antibiotic containing sulfur and D-α -aminoadipinic acid. Nature 175: 548– 556.
52.
Oki, T.,, Y. Matsuzawa,, A. Yoshimoto,, K. Numata,, I. Kitamura,, S. Hori,, A. Takamatsu,, H. Umezawa,, M. Ishizuka,, H. Naganawa,, H. Suda,, M. Hamada,, and T. Takeuchi. 1975. New antitumor antibiotics, aclacinomycins A and B. J. Antibiot. 28: 830– 834.
53.
Omura, S.,, Y. Iwai,, A. Hirano,, A. Nakagawa,, J. Awaya,, H. Tsuchiya,, Y. Takahashi,, and R. Masuma. 1977. A new alkaloid AM-2282 of Streptomyces origin, taxonomy, fermentation, isolation and preliminary characterization. J. Antibiot. 30: 275– 282.
54.
Otoguro, K.,, Z.-H. Liu,, K. Fukuda,, Y. Li,, Y. Iwai,, H. Tanaka,, and S. Omura. 1988. Screening for new nematocidal substances of microbial origin by a new method using the pine wood nematode. J. Antibiot. 41: 573– 575.
55.
Oxford, A. E.,, H. Raistrick,, and P. Simonart. 1939. Studies on the biochemistry of microorganisms. 60. Griseofulvin, C 17H17O6Cl, a metabolic product of Penicillium Dierekx. Biochem. J. 33: 240– 248.
56.
Satomi, T.,, H. Kusakabe,, G. Nakamura,, T. Nishio,, M. Uramoto, and K. Isono. 1982. Neopeptins A and B, new antifungal antibiotics. Agric. Biol. Chem. 46: 2621– 2623.
57.
Schatz, A.,, A. Bugle,, and S. A. Waksman. 1944. Streptomycin, a substance exhibiting antibiotic activity against Gram-positive and Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55: 66– 69.
58.
Schimana, J.,, H.-P. Fiedler,, I. Groth,, R. Süssmuth,, W. Beil,, M. Walker,, and A. Zeeck. 2000. Simocyclinones, novel cytostatic angucyclinone antibiotics produced by Streptomyces antibioticus Tü 6040. J. Antibiot. 53: 779– 787.
59.
Schmidt, D. D.,, W. Frommer,, B. Junge,, L. Muller,, W. Wingender,, and E. Truscheit. 1977. Alpha-glucosidase inhibitors, new complex oligosaccharides of microbial origin. Naturwissensch. 64: 535– 536.
60.
Schulz, B.,, J. Sucker,, H. J. Aust,, K. Krohn,, K. Ludewig,, P. G. Jones,, and D. Döring. 1995. Biologically active secondary metabolites of endophytic Pezicula species. Mycol. Res. 99: 1007– 1015.
61.
Sensi, P.,, P. Margalith,, and M. T. Timbal. 1959. Rifomycin, a new antibiotic. Preliminary report. Farmaco Ed. Sci. 14: 146– 147.
62.
Shull, G. M.,, and J. L. Sardinas. 1955. PA-94, an antibiotic identical with D-4-amino-3-isoxazolidone (cycloserine, oxamycin). Antibiot. Chemother. 5: 398– 399.
63.
Simpkin, K. G.,, and G. C. Coles. 1981. The use of Caenorhabditis elegans for anthelmintic screening. J. Chem. Technol. Biotechnol. 31: 66– 69.
64.
Stapley, E. O.,, J. Birnbaum,, A. K. Miller,, H. Wallick,, D. Hendlin,, and H. B. Woodruff. 1979. Cefoxitin and cephamycins: microbiological studies. Rev. Infect. Dis. 1: 73– 89.
65.
Sternberg, T. H.,, E. T. Wright,, and M. Oura. 1956. A new antifungal antibiotic amphotericin B. Antibiot. Annu. 1955/56: 566– 573.
66.
Takeuchi, T. 1987. Institute of Microbial Chemistry 1962-1987. Microbial Chemistry Research Foundation, Tokyo, Japan.
67.
Tanaka, H.,, K. Kawakita,, N. Imamura,, K. Tsuzuki,, and K. Sh-iomi,. 1992. General screening of enzyme inhibitors, p. 117– 160. In S. Omura (ed.), The Search for Bioactive Compounds from Microorganisms. Springer-Verlag, New York, N.Y.
68.
Tejmar-Kolar, L.,, and H. Zähner. 1984. Search for effective substances against parasitic protozoa: an attempt to develop a new screening model. FEMS MicrobioL Lett. 24: 21– 24.
69.
Umezawa, H. 1982. Low-molecular-weight enzyme inhibitors of microbial origin. Annu. Rev. Microbiol. 36: 75– 99.
70.
Umezawa, H.,, T. Tazaki,, H. Kanari,, Y. Okami,, and S. Fukuyama. 1948. Isolation of crystalline antibiotic substance from a strain of Streptomyces and its identity with chloromycetin. Jpn. Med. J. 1: 358– 363.
71.
Umezawa, H., K. Maeda, T. Takeuchi, and Y. Okami. 1966. New antibiotics, bleomycin A and B. J. Antibiot. 19: 200– 209.
72.
Umezawa, H.,, T. Tsuchiya,, K. Tatsuta,, Y. Horiuchi,, T. Usui,, H. Umezawa,, M. Hamada,, and A. Yagi. 1970. A new antibiotic, dienomycin. I. Screening method, isolation and chemical studies. J. Antibiot. 23: 20– 27.
73.
Vézina, C.,, A. Kudelski,, and S. N. Sehgal. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 28: 721– 726.
74.
Waksman, S. A.,, and H. B. Woodruff. 1940. Bacteriostatic and bactericidal substances produced by soil actinomycetes. Proc. Soc. Exp. Biol. Med. 45: 609– 614.
75.
Waksman, S. A.,, and H. B. Woodruff. 1942. Streptothricin, a new selective bacteriostatic and bactericidal agent particularly against Gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 49: 207– 209.
76.
Wallick, H.,, D. A. Harris,, M. A. Reagan,, and H. B. Woodruff. 1955. Discovery and antimicrobial properties of cathomycin, a new antibiotic produced by Streptomyces spheroides n. sp. Antibiot. Annu. 1955-1956: 909– 917.
77.
Whitfield, G.B.,, T. D. Brock,, A. Ammann,, D. Gottlieb,, and H. E. Carter. 1955. Filipin, an antifungal antibiotic: isolation and properties. J. Am. Chem. Soc. 77: 4799– 4801.
78.
Zähner, H. 1965. Biologie der Antibiotica. Springer, Berlin, Germany.
79.
Zähner, H.,, and H.-P. Fiedler,. 1995. The need for new antibiotics: possible ways forward, p. 67– 84. In G. K. Darby,, P. Hunter,, and D. Russell (ed.), Fifty Years of Antimicrobials. Cambridge University Press, Cambridge, United Kingdom.
80.
Zähner, H.,, H. Drautz,, and W. Weber,. 1982. Novel approaches to metabolite screening, p. 51– 70. In J. D. Bu'Lock,, I. J. Nisbet,, and D. J. Winstanley (ed.), Bioactive Metabolite Products: Search and Discovery. Academic Press, London, United Kingdom.